title: [Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis].
abstract: OBJECTIVE
  To evaluate the efficiency of Remaxol monotherapy in patients with nonalcoholic fatty liver disease (NAFLD) at the stage of steatohepatitis (SH).
  
  
  METHODS
  The treatment of 156 patients with NAFLD at the stage of SH was analyzed. A study group included 84 patients who had received intravenous Remaxol, 400 ml, dropwise at a rate of 40-60 drops per minute once daily in the morning for 10 days; a control group of 72 patients had been treated with the conventional scheme.
  
  
  RESULTS
  During the treatment, the study group showed a rapider relief of the manifestations of asthenovegetative and dyspeptic syndromes and a reduction in the magnitude of biochemical manifestations of cytolytic and cholestatic syndromes than did the control group.
  
  
  CONCLUSIONS
  Incorporation of Remaxol into the therapy regimen in patients with NAFLD at the stage of SH enhances the effectiveness of treatment.
authors.affiliation: Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia.
authors.forename: V A
authors.initials: VA
authors.lastname: Semiserin
authors.affiliation: Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia.
authors.forename: A G
authors.initials: AG
authors.lastname: Karakozov
authors.affiliation: Consulting and Diagnostic Polyclinic, City Clinical Hospital Fifty-Nine, Moscow Healthcare Department, Moscow, Russia.
authors.forename: M A
authors.initials: MA
authors.lastname: Malkuta
authors.affiliation: Consulting and Diagnostic Polyclinic, City Clinical Hospital Fifty-Nine, Moscow Healthcare Department, Moscow, Russia.
authors.forename: L A
authors.initials: LA
authors.lastname: Zolotareva
authors.affiliation: Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia.
authors.forename: O B
authors.initials: OB
authors.lastname: Levchenko
authors.affiliation: Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia.
authors.forename: I E
authors.initials: IE
authors.lastname: Kalyagin
authors.affiliation: Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia.
authors.forename: M N
authors.initials: MN
authors.lastname: Eremin
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage; D019610:Cytoprotection; D004338:Drug Combinations; D016903:Drug Monitoring; D005234:Fatty Liver / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D005260:Female; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D062072:Patient Acuity; D013386:Succinates / Q000008:administration & dosage*; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; C555877:Remaxol; D013386:Succinates